

CNS Pharmaceuticals, Inc.
2100 West Loop South, Suite 900
Houston, TX 77027

November 28, 2023

VIA EDGAR

U.S. Securities and Exchange Commission
Division of Corporate Finance
Washington, DC 20549
Attention: Tyler Howes

Re: CNS Pharmaceuticals, Inc.
Registration Statement on Form S-3
Registration No. 333-275671

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, CNS Pharmaceuticals, Inc., a Nevada corporation (the “Company”), hereby respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:00 P.M. (Eastern Time) on November 30, 2023, or as soon thereafter as possible on such date.

Very truly yours,

CNS Pharmaceuticals, Inc.

By: /s/ Christopher Downs
Name: Christopher Downs
Title: Chief Financial Officer